Saccharomyces cerevisiae yeast, 3D illustration.
Microscopic fungi, baker’s or brewer’s yeast, are used as probiotics to restore normal flora of intestine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic Goods Administration) approval for its advanced wound healing gel TR Pro+, which contains yeast-derived active ingredient Glucoprime.

At 13:25 AEDT, shares in Tissue Repair were trading at 29 cents, a rise of 31.82% since the market opened.

Launched in June last year, TR Pro+ will be suitable for use by those recovering from medical and aesthetic procedures, and has been approved in the gel sizes 10 and 50 grams, as well as 3 gram sachets.

The company stated that the approval would open the door for this product to be marketed for acute wounds and a broad range of derm conditions, given what has been confirmed about its capacity to support skin healing, repair and regeneration.

Even while TR Pro+ was categorised as a cosmetic product, its sales were performing impressively, said Tissue Repair, with 130% revenue growth over the third quarter compared to the prior reporting period, and expanding usage to more than 160 clinics.

TRP by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Big miners jump on bounce in iron ore price | November 18, 2024

The iron ore price has lifted to US$100.15 in Singapore and big miner Rio Tinto (ASX:RIO)…
The Market Online Video

ASX Market Update: Gold bounces back as Iron Ore slides | November 18, 2024

Gold has bounced back to US$2,588 per ounce as investors move part of their portfolios back…
NAB storefront

NAB dips 1.8% as ASIC take bank to court for ignoring hardship applications

Market regulator ASIC is taking NAB to court for allegedly failing to address nearly 350 hardship…